Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
Mounjaro menu plan: What foods to eat and avoid for optimal results
Mounjaro can cause mild to moderate side effects, such as nausea, vomiting, constipation, and indigestion. According to Eli ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
pharmaphorum3d
Lilly’s Mounjaro wins latest head-to-head battle in clinical trials of diabetes treatments
Mounjaro, manufactured by Lilly, may have emerged as the newest ... on other background drugs being administered as a standard of care. A trial can still be conducted without taking a patient ...
pharmaphorum3d
Britain will be first to get new Mounjaro device, says Lilly
Eli Lilly is just weeks away from launching Mounjaro in the UK ... welcomed by patient organisation Diabetes UK, whose head of care, Douglas Twenefour, said: “Supporting people with type ...
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Kenvue isn't growing as quickly as Eli Lilly or Zoetis, but it offers investors a strong starting point for dividend income.